Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 12 May 2006:
Vol. 312. no. 5775, p. 829
DOI: 10.1126/science.312.5775.829b
Prev | Table of Contents | Next

ScienceScope

Leaders at the National Institutes of Health (NIH) are fending off new criticism of their boss, Elias Zerhouni. The kerfuffle began last month when Andrew Marks, editor-in-chief of the Journal of Clinical Investigation, blamed Zerhouni's "Roadmap" of trans-NIH initiatives and large clinical trials for diverting money from investigator-initiated grants. "Obviously you are not a scientist," Marks charged.

In a late April online response, all 27 directors of NIH's institutes and centers called Marks's comments a "personal attack" and a diversion from "the real issues." Marks responds that supportive e-mails show "a substantial divide" between NIH leaders and the community.




To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)